[Complex assessment of metabolic parameters in obese patients treated with xenical].
OBJECTIVE
To study effects of xenical combined with moderately hypocaloric diet on fat tissue mass, carbohydrate and lipid metabolism in patients with metabolic syndrome.


METHODS
The study included 60 patients with body mass index (BMI) over 30 kg/m2, mild and moderate arterial hypertension, dyslipidemia, impaired glucose tolerance (IGT) and diabetes mellitus (DM) type 2. The patients were divided into two groups. 30 patients of group 1 received xenical in a dose 120 mg 3 times a day for 24 weeks. 30 patients of the control group received only the above diet for 24 weeks. The examination included 24-h monitoring of arterial pressure, anthropometric measurements, tests for glycemia, C-peptide, cholesterol, triglycerides (TG), LDLP, HDLP.


RESULTS
Group 1 patients reduced their weight by 10.8 +/- 7.5 kg and fat tissue mass by 9.4 +/- 9.2 kg. This was in correlation with improvement of fatty, carbohydrate metabolism, arterial pressure. After 24 weeks of therapy xenical lowered cholesterol by 15%, LDLP cholesterol by 20%, TG by 28%, systolic and diastolic pressure by 5 and 4%.


CONCLUSIONS
Combination of xenical with hypocaloric diet can be used in therapy of patients with metabolic syndrome.
Ametov
A S
AS
Demidova
T Iu
TIu
Tselikovskaia
A L
AL
D019440:Anti-Obesity Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001794:Blood Pressure / Q000502:physiology; D001837:Body Weights and Measures; D005260:Female; D006801:Humans; D007333:Insulin Resistance; D007783:Lactones / Q000008:administration & dosage / Q000627:therapeutic use*; D008055:Lipids / Q000097:blood; D008297:Male; D009765:Obesity / Q000178:diet therapy / Q000188:drug therapy / Q000378:metabolism* / Q000503:physiopathology; D000077403:Orlistat; D016896:Treatment Outcome
D019440:Anti-Obesity Agents; D007783:Lactones; D008055:Lipids; D000077403:Orlistat